Low-dose radiotherapy synergizes with PD-1 blockade to achieve durable survival in advanced NSCLC through antitumor neutrophil programming

Key Points

• This research aims to determine the synergy between low-dose radiotherapy and PD-1 blockade to improve survival in advanced non-small cell lung cancer (NSCLC).
• Conducted a randomized trial involving advanced NSCLC patients.
• Administered low-dose radiotherapy alongside PD-1 blockade therapy.
• Evaluated neutrophil programming effects on antitumor responses.
• Reported durable survival benefits with combined therapy; event rates detailed not provided.
• Indicated improved antitumor efficacy through neutrophil programming; statistical outcomes not specified.